Actively Recruiting

Phase 2
Age: 15Years +
All Genders
NCT05383742

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2025-12-02

330

Participants Needed

18

Research Sites

301 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC) treatment for tuberculosis meningitis (TBM).

CONDITIONS

Official Title

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Who Can Participate

Age: 15Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of definite, probable, or possible tuberculous meningitis with commitment to full standard anti-TB treatment
  • Negative or documented positive HIV-1 infection confirmed by specific tests
  • Documentation of disease stage using BMRC TBM grade within 3 days prior to entry
  • Laboratory values within 3 days prior: serum creatinine ≤1.8 x ULN, hemoglobin ≥8.0 g/dL for men or ≥7.5 g/dL for women, absolute neutrophil count ≥600/mm3, platelet count ≥60,000/mm3, ALT ≤3 x ULN, total bilirubin ≤2 x ULN
  • Negative pregnancy test within 21 days if of reproductive potential and not surgically sterile
  • Agreement to use contraception or abstain from pregnancy-risk activities during treatment and 30 days after
  • Ability and willingness to provide informed consent or assent
  • Ability to comply with study protocol requirements as judged by site investigator
Not Eligible

You will not qualify if you...

  • More than 14 cumulative days of first-line TB medications within 90 days prior to entry
  • Known current or prior drug-resistant TB infection
  • Known allergy or hypersensitivity to study drugs or their components
  • Grade 3 subjective peripheral neuropathy with vibratory loss or absent ankle jerks if screened
  • Planned or recent use of medications with significant interactions with study drugs
  • For HIV-positive participants, planned initiation or reinitiation of ART during screening or first 4 weeks of TB therapy
  • Contraindication to lumbar puncture by clinician judgment
  • Positive test within 21 days prior to entry indicating CNS infection other than TBM (e.g., cryptococcal or bacterial meningitis)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Hospital Nossa Senhora da Conceicao CRS (Site ID: 12201)

Porto Alegre, Brazil, 91350-200

Actively Recruiting

2

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)

Rio de Janeiro, Brazil

Actively Recruiting

3

Byramjee Jeejeebhoy Government Medical College (BJMC) CRS (Site ID: 31441)

Pune, India, 411001

Actively Recruiting

4

Moi University Clinical Research Center (MUCRC) CRS (Site ID: 12601)

Eldoret, Kenya, 30100

Actively Recruiting

5

Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (Site ID: 12501)

Kericho, Kenya

Actively Recruiting

6

Malawi CRS (Site ID: 12001)

Lilongwe, Malawi

Actively Recruiting

7

Nutrición-Mexico CRS (Site ID: 32078)

Mexico City, Mexico, 14080

Not Yet Recruiting

8

Socios en Salud Sucursal Peru CRS (Site ID: 31985)

Lima, Peru, 15046

Not Yet Recruiting

9

Barranco CRS (Site ID:11301)

Lima, Peru, 4

Not Yet Recruiting

10

TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981)

Cavite, Philippines, 4114

Not Yet Recruiting

11

Durban International CRS (Site ID:11201)

Durban, South Africa, 4091

Not Yet Recruiting

12

University of the Witwatersrand Helen Joseph (WITS HJH) CRS (Site ID: 11101)

Johannesburg, South Africa, 2193

Not Yet Recruiting

13

Kilimanjaro Christian Medical Centre (KCMC) (Site ID: 5118)

Moshi, Tanzania

Not Yet Recruiting

14

Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115)

Bangkok, Bangkoknoi, Thailand, 10700

Not Yet Recruiting

15

Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)

Bangkok, Pathumwan, Thailand, 10330

Not Yet Recruiting

16

Chiangrai Prachanukroh Hospital NICHD CRS (Site ID: 5116)

Chiang Mai, Thailand, 50100

Actively Recruiting

17

National Lung Hospital CRS (Site ID: 32483)

Vĩnh Phúc, Hanoi, Vietnam, 100000

Actively Recruiting

18

Milton Park CRS (Site ID: 30313)

Harare, Zimbabwe

Actively Recruiting

Loading map...

Research Team

A

ACTG Clinicaltrials.gov Coordinator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here